Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.92
-0.07 (-0.78%)
Mar 3, 2026, 4:00 PM EST - Market closed
Emergent BioSolutions Revenue
In the year 2025, Emergent BioSolutions had annual revenue of $742.90M, down -28.81%. Emergent BioSolutions had revenue of $148.70M in the quarter ending December 31, 2025, a decrease of -23.63%.
Revenue (ttm)
$742.90M
Revenue Growth
-28.81%
P/S Ratio
0.62
Revenue / Employee
$825,444
Employees
900
Market Cap
461.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 742.90M | -300.70M | -28.81% |
| Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
| Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
| Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
| Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
| Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
| Dec 31, 2019 | 1.11B | 323.60M | 41.36% |
| Dec 31, 2018 | 782.40M | 221.50M | 39.49% |
| Dec 31, 2017 | 560.90M | 72.10M | 14.75% |
| Dec 31, 2016 | 488.80M | -531.00K | -0.11% |
| Dec 31, 2015 | 489.33M | 84.87M | 20.98% |
| Dec 31, 2014 | 404.47M | 91.72M | 29.33% |
| Dec 31, 2013 | 312.75M | 30.86M | 10.95% |
| Dec 31, 2012 | 281.89M | 8.50M | 3.11% |
| Dec 31, 2011 | 273.38M | -12.79M | -4.47% |
| Dec 31, 2010 | 286.17M | 51.39M | 21.89% |
| Dec 31, 2009 | 234.79M | 56.23M | 31.49% |
| Dec 31, 2008 | 178.55M | -4.36M | -2.38% |
| Dec 31, 2007 | 182.92M | 30.18M | 19.76% |
| Dec 31, 2006 | 152.73M | 22.04M | 16.87% |
| Dec 31, 2005 | 130.69M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 564.17M |
| Ironwood Pharmaceuticals | 296.15M |
| Evolus | 285.82M |
| Akebia Therapeutics | 236.20M |
| Canopy Growth | 203.04M |
| Kamada | 174.79M |
| SIGA Technologies | 172.25M |
| Lifecore Biomedical | 128.87M |
EBS News
- 21 hours ago - Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors - GlobeNewsWire
- 3 days ago - Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture - Seeking Alpha
- 5 days ago - Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 5 days ago - Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 5 days ago - Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness - GlobeNewsWire
- 5 days ago - Emergent BioSolutions Announces New $50 Million Stock Repurchase Program - GlobeNewsWire
- 19 days ago - Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks - GlobeNewsWire
- 19 days ago - Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire